If biotech funding continues to increase this year, Danaher could benefit.

WASHINGTON — Biotech breakthroughs are within U.S. reach, but policy shifts and proposed funding cuts could slow how those ...

Introducing CPC Biotech - one brand uniting critical fluid management components New brand unites CPC’s Biopharma connector ...

After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a path forward ...

Legend Biotech ( LEGN +18.42%) was one of the healthier healthcare stocks on the market as the trading week kicked off on ...

The deal for Kelonia Therapeutics is valued at $3.25 billion upfront.

The high-profile obesity drug developer priced the biotech sector’s biggest offering in years and will use the proceeds to ...

Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech ...

Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...

But in the last three years, the company has sought to leverage its footholds in China and the U.S. to become a multinational ...